# FORSYTH BARR

Access

NEW ZEALAND EQUITY RESEARCH AGED CARE AGED CARE 16 JUNE 2025

# **Radius Residential Care** Beginning FY26 on the Right ARC

#### JAMES LINDSAY

james.lindsay@forsythbarr.co.nz +64 9 368 0145

#### WILL TWISS

will.twiss@forsythbarr.co.nz +64 9 368 0129

Radius Residential Care (RAD) provided an upbeat trading update not long after its FY25 result announcement, with operational performance in 1H26 tracking significantly ahead of the prior corresponding period, albeit broadly in line with our underlying expectations. Underlying EBITDA for 1H26 is expected to be in the range of NZ\$12m-NZ\$15m, +27% ahead of 1H25 at the midpoint. The improved performance is being driven by: (1) strong occupancy; (2) a favourable bed mix (more high-acuity residents); (3) accommodation supplement growth; and (4) increased resales. RAD also expects to realise interest cost savings of more than NZ\$1m (~-15%) in FY26. We have increased our earnings forecasts, and our blended spot valuation rises to NZ\$0.42. Indications are that the government will provide a +4% funding increase (versus ~+2% expected) from 1 July 2025, which would provide further upside to our numbers if confirmed.

NZX code	RAD	Financials: Mar/	25A	26E	27E	28E	Valuation (x)	25A	26E	27E	28E
Share price	NZ\$0.30	Rev (NZ\$m)	177.4	191.0	196.3	201.9	PE	11.4	6.9	6.1	5.6
Spot Valuation	NZ\$0.42 (from 0.40)	NPAT* (NZ\$m)	7.4	12.1	13.7	15.1	EV/EBIT	12.6	9.4	8.9	8.5
Risk rating	Medium	EPS* (NZc)	2.6	4.3	4.8	5.3	EV/EBITDA	8.5	7.1	6.8	6.6
Issued shares	284.6m	DPS (NZc)	1.5	1.9	2.2	2.4	Price / NTA	1.7	1.3	1.1	0.9
Market cap	NZ\$84m	Imputation (%)	100	100	100	100	Cash div yld (%)	4.9	6.4	7.3	8.1
Avg daily turnover	89.2k (NZ\$19k)	*Based on normalised profits					Gross div yld (%)	6.8	8.9	10.1	11.3

#### What's changed?

- Earnings: Underlying EBITDA increases +1%, +1%, and +2% across FY26, FY27, and FY28 respectively.
- Spot valuation: Rises +2cps to NZ\$0.42.

#### Impressive operational performance continues

RAD continues to exhibit robust operational momentum, underpinned by a strong, rising occupancy trend. Occupancy has averaged in the 94%–95% range in the opening two and a half months of FY26, up from 92.8% in FY25. This is in line with our 94.4% FY26 occupancy forecast. RAD is also executing well on two key pillars of its aged care strategy: shifting towards a higher-acuity bed mix and increasing accommodation supplement revenue.

#### Interest cost reductions support NPAT and AFFO

RAD expects interest costs on bank debt to decline by more than ~-NZ\$1m in FY26, implying a larger than ~-100 bp decrease in its weighted interest rate for FY26. Just over 40% of RAD's bank debt is hedged, with the remainder floating based on the bank bill benchmark rate.

#### Funding increases provide further upside

Industry feedback suggests the government's latest funding round could deliver a ~+4% increase in the per day bed rate for aged care providers, effective 1 July 2025 (see Figure 2). While not confirmed and not factored into our forecasts at this stage, this would represent a more favourable outcome than the ~+2% increase we were expecting and would likely be an incremental positive for the wider aged residential care (ARC) sector. We estimate the incremental benefit for RAD of an extra +200 bp funding increase could be north of +NZ\$2m in annualised underlying EBITDA.

#### Radius Residential Care Limited (RAD)

Priced as at 15 Jun 2025					0.30
52 week high / low				C	0.31/0.14
Market capitalisation (NZ\$m)					84.0
Carbon and ESG (CESG)**					
CESG rating					n/a
CESG score					n/a
Sector average CESG score					n/a
NZ average CESG score					n/a
Profit and Loss Account (NZ\$m)	2024A	2025A	2026E	2027E	20285
Revenue	171.2	177.4	191.0	196.3	201.9
Normalised EBITDA	29.6	32.3	39.1	41.4	43.0
Depreciation and amortisation	(9.9)	(10.4)	(10.5)	(10.6)	(10.8
Normalised EBIT	19.7	21.9	28.6	30.8	32.2
Net interest	(15.5)	(12.0)	(11.4)	(11.4)	(10.8
Associate income	-	-	-	-	
Tax	(12.1)	(3.1)	(5.1)	(5.7)	(6.2)
Minority interests	-		-	-	
Normalised NPAT	3.5	7.4	12.1	13.7	15.1
Abnormals/other	(11.9)	0.0	1.0	1.1	0.9
Reported NPAT	(8.5)	7.4	13.1	14.7	16.0
Normalised EPS (cps)	1.2	2.6	4.3	4.8	5.3
DPS (cps)	0.7	1.5	1.9	2.2	2.4
Growth Rates	2024A	2025A	2026E	2027E	2028
Revenue (%)	17.1	3.6	7.7	2.8	2.9
EBITDA (%)	30.5	9.2	20.9	5.9	3.9
EBIT (%)	>100	15.4	34.6	7.5	4.1
Normalised NPAT (%)	>100	>100	64.9	12.7	10.5
Normalised EPS (%)	>100	>100	65.0	12.7	10.5
Ordinary DPS (%)	0.0	>100	31.0	13.2	11.6
Cash Flow (NZ\$m)	2024A	2025A	2026E	2027E	20288
EBITDA	29.6	32.3	39.1	41.4	43.0
Working capital change	(3.7)	2.8	(3.3)	(0.9)	(0.8
Interest & tax paid	(14.0)	(13.1)	(16.5)	(17.1)	(17.1
Other	2.3	(1.9)	-	-	
Operating cash flow	14.1	20.1	19.3	23.4	25.1
Capital expenditure	(3.5)	(5.8)	(9.0)	(8.1)	(8.4)
(Acquisitions)/divestments	-	(0.9)	-	-	-
Other	(3.4) <b>7.3</b>	(3.4)	(3.5)	(3.7)	(4.2)
Funding available/(required) Dividends paid	7.3	<b>9.8</b> (3.8)	6.7	11.6	12.6
	-		(4.6)	(5.7)	(6.4)
Equity raised/(returned) (Increase)/decrease in net debt	7.3	(0.0) <b>5.9</b>	2.2	5.9	6.2
Balance Sheet (NZ\$m)	2024A	2025A	2026E	2027E	20288
				(5.5)	(5.2
Working capital Fixed assets	(4.4) 117.3	(8.8) 118.2	(6.0) 121.9	(5.5) 124.7	127.6
Intangibles	117.3	118.2	121.7	124.7	127.0
Right of use asset	10.1	109.5	117.9	112.7	107.3
Other assets	73.5	77.1	83.8	90.9	98.4
Total funds employed	312.4	314.1	335.8	340.8	346.1
Net debt/(cash)	73.5	67.7	65.6	59.7	53.5
Lease liability	121.1	122.7	132.8	129.1	124.9
Other liabilities	46.7	47.7	46.6	47.9	49.3
Shareholder's funds	71.1	76.0	40.0 90.9	104.1	118.4
Minority interests		, 0.0	-	10	110
Total funding sources	312.4	314.1	335.8	340.8	346.1

Spot valuation (NZ\$)					0.42
Comparable relative					0.41
DCF					0.44
Dividend Discount Model (DDM)					0.38
Key WACC assumptions					=
Risk free rate					5.00%
Equity beta WACC					1.19 9.6%
Terminal growth					1.5%
iernina growar					1.570
Valuation Ratios	2024A	2025A	2026E	2027E	2028E
EV/Sales (x)	1.7	1.6	1.5	1.5	1.4
EV/EBITDA (x)	9.9	8.5	7.1	6.8	6.6
EV/EBIT (x)	15.3	12.6	9.4	8.9	8.5
PE (x)	24.3	11.4	6.9	6.1	5.6
Price/NTA (x)	1.8	1.7	1.3	1.1	0.9
Free cash flow yield (%)	9.5	13.4	8.0	13.8	15.0
Adj. free cash flow yield (%)	10.5	14.0	11.7	16.2	17.5
Net dividend yield (%)	2.4	4.9	6.4	7.3	8.1
Gross dividend yield (%)	3.3	6.8	8.9	10.1	11.3
Capital Structure	2024A	2025A	2026E	2027E	2028E
Interest cover EBIT (x)	1.2	1.8	2.6	2.8	3.1
Interest cover EBITDA (x)	1.9	2.7	3.4	3.6	4.0
Net debt/ND+E (%)	54.4	50.0	44.2	38.4	32.7
Net debt/EBITDA (x)	2.5	2.1	1.7	1.4	1.2
Key Ratios	2024A	2025A	2026E	2027E	2028E
Return on assets (%)	5.7	6.5	8.2	8.6	8.7
Return on equity (%)	5.6	10.8	14.7	14.3	13.7
Return on funds employed (%)	0.9	1.9	2.9	3.2	3.5
EBITDA margin (%)	17.3	18.2	20.5	21.1	21.3
EBIT margin (%)	11.1	12.4	15.5	16.2	16.4
Capex to sales (%)	2.0	3.3	4.7	4.1	4.1
Capex to depreciation (%)	-35	-57	-86	-77	-77
Imputation (%)	100	100	100	100	100
Pay-out ratio (%)	58	56	45	45	45
Operating Performance	2024A	2025A	2026E	2027E	2028E
Segment EBITDA	2024A	ZUZJA	20201	20271	2020L
Aged care	42.7	46.2	51.1	53.0	54.3
Retirement villages	4.5	2.9	4.5	4.7	5.1
Support	-17.6	-16.7	-16.5	-16.3	-16.4
Total	29.6	32.4	-10.5 39.1	-10.3 <b>41.4</b>	43.0
lotai	27.0	52.4	57.1	41.4	40.0
Key drivers					
Sales - new units	0	0	6	6	6
Ave price - new sales (NZ 000's)	0	500	500	515	530
Sales - resold units	28	18	20	21	22
Ave price - re-sales (NZ 000's)	390	427	440	453	467
Gross development margin	0%	0%	5%	5%	10%
Gross resales margin	16%	19%	19%	19%	19%
-					
Portfolio					
Care beds	1,789	1,789	1,898	1,898	1,898
Care bed occupancy	92%	93%	94%	95%	95%
Accomodation supplement beds	1,217	1,217	1,296	1,301	1,305
% of beds with supplements	68%	68%	68%	69%	69%

Access

\* Forsyth Barr target prices reflect valuation rolled forward at cost of equity less the next 12months dividend\*\* Information on Forsyth Barr's Carbon and ESG (CESG) ratings can be found at www.forsythbarr.co.nz/corporate-news-events/cesg-report



## **Earnings revisions**


We make minor changes to our underlying EBITDA forecasts, with operational performance tracking broadly in line with our expectations. However, NPAT attributable to shareholders rises +17% in FY26 and +15% in FY27 and FY28 due to increased fair value changes and reduced finance costs.

#### Figure 1. Earnings revisions (NZ\$m)

		FY26E			FY27E			FY28E	
	Old	New	Change	Old	New	Change	Old	New	Change
Total revenue and other income	192.7	194.5	+1%	198.0	200.0	+1%	203.8	206.0	+1%
Employee costs	(111.0)	(111.1)	+0%	(112.7)	(112.8)	+0%	(115.8)	(115.9)	+0%
Depreciation	(10.5)	(10.5)	+0%	(10.6)	(10.6)	+0%	(10.8)	(10.8)	+0%
Finance costs	(11.9)	(11.5)	-4%	(11.9)	(11.5)	-4%	(11.6)	(11.1)	-4%
Other expenses	(43.5)	(43.2)	-1%	(44.9)	(44.6)	-1%	(46.1)	(45.8)	-1%
Total expenses	(176.9)	(176.3)	-0%	(180.1)	(179.5)	-0%	(184.3)	(183.7)	-0%
Profit (loss) before income tax	15.8	18.2	+16%	17.8	20.4	+15%	19.5	22.3	+14%
Income tax expense	(4.4)	(5.1)	+16%	(5.0)	(5.7)	+15%	(5.5)	(6.2)	+14%
NPAT	11.3	13.1	+16%	12.9	14.7	+15%	14.1	16.0	+14%
NPAT attributable to shareholders	10.8	12.6	+17%	12.3	14.1	+15%	13.4	15.4	+15%
Basic and diluted eps	0.040	0.046	+16%	0.045	0.052	+15%	0.049	0.056	+14%
DPS	0.019	0.019	+3%	0.021	0.022	+2%	0.024	0.024	+2%
Underlying EBITDA (post leases)	28.8	29.1	+1%	30.7	31.2	+1%	31.9	32.5	+2%


Source: Forsyth Barr analysis

#### Figure 2. RAD-Underlying EBITDA



Source: Company, Forsyth Barr analysis

#### Figure 3. MOH average contract rates increases (%)



Source: MoH, Forsyth Barr analysis, \* Preliminary MOH Contract Rate Adjustment for 2025

# FORSYTH BARR



# **Additional data**

#### Figure 4. Share price performance



#### Figure 5. Substantial shareholders

Shareholder	Latest Holding
Kade Kings Limited	33.5%
Windhaven	10.6%
Neil Foster	5.5%
Main Family Trust	5.4%

Source: NZX, Forsyth Barr analysis, NOTE: based on SPH notices only


Source: LSEG, Forsyth Barr analysis

#### Figure 6. International valuation comparisons using consensus data (one and two year forward)

Company	Code	Price	Mkt Cap	PE		EV/EBITDA		EV/EBIT		Cash Yld
			(m)	1yr	2yr	1yr	2yr	1yr	2yr	1yr
Radius Residential Care	RAD NZ	NZ\$0.30	NZ\$84	8.0x	6.9x	11.4x	10.6x	15.8x	14.5x	6.1%
Oceania Healthcare	OCA NZ	NZ\$0.62	NZ\$449	9.0x	7.4x	13.1x	11.8x	17.5x	15.4x	0.6%
Ryman Healthcare	RYM NZ	NZ\$2.17	NZ\$2,204	33.9x	20.9x	25.8x	18.9x	26.1x	22.2x	0.1%
Summerset	SUM NZ	NZ\$11.29	NZ\$2,720	10.8x	9.4x	13.7x	12.5x	15.8x	14.0x	2.3%

Source: Forsyth Barr analysis, Bloomberg, NOTE: all multiples based on Bloomberg consensus estimates, EV = market cap+net debt+lease liabilities+min interests-investments

#### Figure 7. Consensus EPS momentum (NZ\$)



Source: Bloomber, Forsyth Barr analysis

# FORSYTH BARR



### **Disclosures**

#### Important information about this publication

Forsyth Barr Limited ("**Forsyth Barr**") holds a licence issued by the Financial Markets Authority to provide financial advice services. In making this publication available, Forsyth Barr (and not any named analyst personally) is giving any financial advice it may contain. Some information about us and our financial advice services is publicly available. You can find that on our website at <u>www.forsythbarr.co.nz/choosing-a-financial-advice-service</u> Please note the limitations in relation to distribution generally, and in relation to recipients in Australia in particular, as set out under those headings below.

This publication has been commissioned by Radius Residential Care ("**Researched Entity**") and prepared and issued by Forsyth Barr in consideration of a fee payable by the Researched Entity. Forsyth Barr follows a research process (including through the Analyst certification below) designed to ensure that the recommendations and opinions in our research publications are not influenced by this arrangement and the other interests of Forsyth Barr and related parties disclosed below. However, entities may not be willing to continue to pay for research coverage that includes unfavourable views.

Any recommendations or opinions in this publication do not take into account your personal financial situation or investment goals, and may not be suitable for you. If you wish to receive personalised financial advice, please contact your Forsyth Barr Investment Adviser.

Past performance is not indicative of future performance. Estimates of future performance are based on assumptions that may not be realised. If provided, and unless otherwise stated, the closing price provided is that of the primary exchange for the issuer's securities or investments.

This publication has been prepared in good faith based on information obtained from sources believed to be reliable and accurate. However, that information has not been independently verified or investigated by Forsyth Barr. If there are material inaccuracies or omissions in the information it is likely that our recommendations or opinions would be different. Any analyses or valuations will also typically be based on numerous assumptions (such as the key WACC assumptions); different assumptions may yield materially different results.

Forsyth Barr does not undertake to keep current this publication; any opinions or recommendations may change without notice to you.

In giving financial advice, Forsyth Barr is bound by duties under the Financial Markets Conduct Act 2013 ("FMCA") to:

- exercise care, diligence, and skill,
- give priority to the client's interests, and

• when dealing with retail clients, comply with the Code of Professional Conduct for Financial Advice Services, which includes standards relating to competence, knowledge, skill, ethical behaviour, conduct, and client care.

There are likely to be fees, expenses, or other amounts payable in relation to acting on any recommendations or opinions in this publication. If you are Forsyth Barr client we refer you to the Advice Information Statement for your account for more information.

Analyst certification: The research analyst(s) primarily responsible for the preparation and content of this publication ("Analysts") are named on the first page of this publication. Each such Analyst certifies (other than in relation to content or views expressly attributed to another analyst) that (i) the views expressed in this publication accurately reflect their personal views about each issuer and financial product referenced; and (ii) no part of the Analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that Analyst in this publication.

Analyst holdings: The following Analyst(s) have a threshold interest in the financial products referred to in this publication: N/A.For these purposes, a threshold interest is defined as being a holder of more than \$50,000 in value or 1% of the financial products on issue, whichever is the lesser.

Other disclosures: Forsyth Barr and its related companies (and their respective directors, officers, agents and employees) ("Forsyth Barr Group") may have long or short positions or otherwise have interests in the financial products referred to in this publication, and may be directors or officers of, and/or provide (or be intending to provide) corporate advisory or other services to, the issuer of those financial products (and may receive fees for so acting). Members of the Forsyth Barr Group may buy or sell financial products as principal or agent, and in doing so may undertake transactions that are not consistent with any recommendations contained in this publication. Other Forsyth Barr business units may hold views different from those in this publication; any such views will generally not be brought to your attention. Forsyth Barr confirms no inducement has been accepted from the issuer(s) that are the subject of this publication, whether pecuniary or otherwise, in connection with making any recommendation contained in this publication. In preparing this publication, non-financial assistance (for example, access to staff or information) may have been provided by the issuer(s) being researched.

**Corporate advisory engagements:** Other than confidential engagements, Forsyth Barr has not within the past 12 months been engaged to provide corporate advisory services to the Researched Entity.

Complaints: Information about Forsyth Barr's complaints process and our dispute resolution process is available on our website - www.forsythbarr.co.nz.

**Disclaimer**: Where the FMCA applies, liability for the FMCA duties referred to above cannot by law be excluded. However to the maximum extent permitted by law, Forsyth Barr otherwise excludes and disclaims any liability (including in negligence) for any loss which may be incurred by any person acting or relying upon any information, analysis, opinion or recommendation in this publication. The information contained within this publication is published solely for information purposes and is not a solicitation or offer to buy or sell any financial instrument or participate in any trading or investment strategy.

**Distribution**: This publication is not intended to be distributed or made available to any person in any jurisdiction where doing so would constitute a breach of any applicable laws or regulations or would subject Forsyth Barr to any registration or licensing requirement within such jurisdiction.

Recipients in Australia: This publication is only available to "wholesale clients" within the meaning of section 761G of the Corporations Act 2001 (Cth) (" wholesale clients"). In no circumstances may this publication be made available to a "retail client" within the meaning of section 761G. Further, this publication is only available on a limited basis to authorised recipients in Australia. Forsyth Barr is a New Zealand company operating in New Zealand that is regulated by the Financial Markets Authority of New Zealand and NZX. This publication has been prepared in New Zealand in accordance with applicable New Zealand laws, which may differ from Australian laws. Forsyth Barr does not hold an Australian financial services licence. This publication may refer to a securities offer or proposed offer which is not available to investors in Australia, or is only available on a limited basis, such as to professional investors or others who do not require prospectus disclosure under Part 6D.2 of the Corporations Act 2001 (Cth) and are wholesale clients.

Forsyth Barr has been engaged and paid by the company covered in this report for ongoing research coverage. Please refer to the full disclaimers and disclosures.



**Terms of use**: Copyright Forsyth Barr Limited. You may not redistribute, copy, revise, amend, create a derivative work from, extract data from, or otherwise commercially exploit this publication in any way. By accessing this publication via an electronic platform, you agree that the platform provider may provide Forsyth Barr with information on your readership of the publications available through that platform.